C., Usui, W
Il 36% dei pazienti arruolati aveva prediabete al basale: alla 72 settimana, il ritorno alla normoglicemia si osservato nel 74,683,7% dei pazienti trattati con orforglipron (a seconda della dose), contro il 44,6% del placebo (Wharton et al., 2025)
Secondary hypogonadism is where there is a problem in the hypothalamus or pituitary area of the brain
Semaglutide weight loss in Salt Lake City has become an increasingly popular option for individuals seeking medical support for sustainable weight loss
Significance of FDA Approval Sally Seymour, M.D., director of the Division of Pulmonology, Allergy and Critical Care at the FDA, underscored the significance of this landmark decision, noting that it introduces the first drug treatment option for certain patients with OSA